Loren Data's SAM Daily™

FBO DAILY ISSUE OF JULY 31, 2002 FBO #0241
SOLICITATION NOTICE

A -- Development and Testing of a Modified Vaccinia Ankara (MVA) Vaccine

Notice Date

7/29/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Branch 6700-B Rockledge Drive, MSC 7612 Room 2230, Bethesda, MD, 20892-7612
 

ZIP Code

20892-7612
 

Solicitation Number

RFP-NIH-NIAID-DMID-03-44
 

Response Due

9/30/2002
 

Point of Contact

Thomas Hastings, Contracting Officer, Phone 301-496-0194, Fax 301-402-0972, - Jacqueline Holden, Senior Contracting Officer, Phone 301-496-7119, Fax 301-402-0972,
 

E-Mail Address

ph23k@nih.gov, jh55b@nih.gov
 

Description

The Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), NIH, has a requirement for the development and testing of a Modified Vaccinia Ankara (MVA) Vaccine. The purpose of this RFP is to provide resources for the initial development of MVA vaccine candidates. It is the intent of the Government to provide contract support for the development and stockpiling of MVA vaccines through the issuance of sequential RFPs. This current RFP (NIH-NIAID-DMID-03-44) is intended to provide resources for the initial development of MVA vaccine candidates. It is anticipated that one (1) or more cost reimbursement, completion type contracts will be awarded for a period of three (3) years, beginning approximately January 31, 2003. This RFP also includes a Part B to the Statement of Work as an Option provision under FAR 17.2. RFP-NIH-NIAID-DMID-03-44 will be available electronically on or about August 15, 2002, and may be accessed through the NIAID Contract Management Branch (CMB) Home Page http://www.niaid.nih.gov/contract, and will be posted on FedBizOpps. Any responsible Offeror may submit a proposal that will be considered by the Government. This advertisement does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. In addition, the Government intends to issue a second RFP, entitled Production and Acquisition of MVA Vaccine, on or about June 2003. The main objectives of the second RFP will be to: a) execute a plan to manufacture, formulate, fill and finish, and test, assuming 30 X 106 doses of MVA in accordance with cGMP regulations; b) deliver to the Government up to 30 million doses of vaccine to constitute a stockpile for emergency use under IND, and to maintain the stockpile as needed; and c) provide a licensure plan to include the conduct of expanded human safety studies required for licensure and the conduct of pivotal animal protection studies. Participation in RFP NIH-NIAID-DMID-03-44 will not be a pre-requisite for participation in the second RFP, Production and Acquisition of MVA Vaccine; the second RFP will be a full and open, competitive acquisition.
 

Place of Performance

Address: To Be Determined

Zip Code: TBD

Country: TBD
 

Record

SN00127272-W 20020731/020729213250 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |